Xencor (XNCR) EBITDA Margin (2013 - 2026)
Xencor (XNCR) reported EBITDA Margin of 2888.95% for Q1 2026, down 274414.0% year-over-year from N/an in Q1 2025, and down 12549.29% quarter-over-quarter from 22.84% in Q4 2025.
Xencor (XNCR) EBITDA Margin (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of EBITDA Margin data on file, last reported at 2888.95% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 2888.95%, down 274414.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 177.65% (down 1542.0% YoY), and the FY2025 annual result was 71.59%, up 14071.0% from the prior year.
- EBITDA Margin eased to 2888.95% in Q1 2026 per XNCR's latest filing, from 22.84% in the prior quarter.
- Over five years, EBITDA Margin peaked at 21.03% in Q1 2022 and troughed at 2888.95% in Q1 2026.
- A 5-year average of 290.83% and a median of 84.75% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin surged 32331 bps in 2025, then sank 274414 bps in 2026.
- A 5-year view of EBITDA Margin shows it stood at 42.21% in 2022, then retreated by 12 bps to 47.34% in 2023, then sank by 79 bps to 84.75% in 2024, then surged by 73 bps to 22.84% in 2025, then tumbled by 12549 bps to 2888.95% in 2026.
- Business Quant data shows XNCR's EBITDA Margin at 2888.95% in Q1 2026, 22.84% in Q4 2025, and 24.42% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | -2,888.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,888.95% |
| Dec 31, 2025 | -22.84% |
| Sep 30, 2025 | -24.42% |
| Jun 30, 2025 | -70.91% |
| Mar 31, 2025 | -144.81% |
| Dec 31, 2024 | -84.75% |
| Sep 30, 2024 | -252.81% |
| Jun 30, 2024 | -289.79% |
| Mar 31, 2024 | -468.12% |
| Dec 31, 2023 | -47.34% |
| Sep 30, 2023 | -39.07% |
| Jun 30, 2023 | -44.35% |
| Mar 31, 2023 | -302.90% |
| Dec 31, 2022 | -42.21% |
| Sep 30, 2022 | -123.41% |
| Jun 30, 2022 | -118.54% |
| Mar 31, 2022 | 21.03% |
| Dec 31, 2021 | 46.51% |
| Sep 30, 2021 | -204.49% |
| Jun 30, 2021 | 77.30% |